Clinical trial
Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects
NCT00255138 · Temple University, Other · Withdrawn
Key facts
| NCT number | NCT00255138 |
|---|---|
| Title | Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects |
| Official title | Efficacy of Atomoxetine Therapy Versus Placebo For Ameliorating Cognitive Late Effects Among Survivors of Childhood Cancers |
| Lead sponsor | Temple University, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer, Cognitive Late Effects |
| Intervention type | Drug |
| Interventions | Atomoxetine |
| Enrollment | 0 |
| Start date | Nov 1, 2005 |
| First posted | Nov 17, 2005 |
| Last update posted | Apr 1, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: